Anders Lilja is Senior Vice President Infectious Diseases at HOOKIPA. He is responsible for developing HOOKIPA’s infectious disease vaccine candidates. He joined HOOKIPA as Project Leader and led the development of our cytomegalovirus vaccine candidate HB-101 through the first clinical trial. He then took over the leadership of Technical Development at a critical point in the history of HOOKIPA and oversaw a doubling in size of the department, a substantial improvement of the manufacturing process, the development and validation of new product-specific assays, and the GMP production of several batches of product for multiple programs. Prior to joining HOOKIPA, he was a Research Investigator and Associate Research Project Leader at Novartis Vaccines. Dr. Lilja holds an MSc in chemical engineering from Chalmers University of Technology, Sweden, a PhD in Biochemistry from University of Maryland, and did postdoctoral training in molecular virology at Princeton University. He has co-authored several publications characterizing key cytomegalovirus vaccine antigens.